AURE vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 20, 2026

AURE

34.8
AI Score
VS
HIVE Wins

HIVE

60.8
AI Score

Investment Advisor Scores

AURE

35score
Recommendation
SELL

HIVE

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AURE HIVE Winner
Revenue 639,912 297.79M HIVE
Net Income -6.88M -148.45M AURE
Net Margin -1074.7% -49.8% HIVE
ROE -226.2% -28.0% HIVE
ROA -108.7% -23.2% HIVE
Total Assets 6.33M 639.15M HIVE
Cash 13,190 23.11M HIVE
Current Ratio 1.12 1.10 AURE

Relative Price Performance (Last 90 Days)

AURE 1M: -1.8% · 3M: -31.8% HIVE 1M: -3.4% · 3M: -29.7%

Current Technical Phase

AURE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 43

RSI (14): 42.5 · Price: $1.67

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.9 · Price: $2.86

Fundamentals Snapshot

Metric AURE HIVE
Market Cap
Forward P/E 0.0 -5.6
Trailing P/E
Revenue (TTM)
Revenue Growth -1.0% 0.7%
Gross Margin 1.0% 0.4%
Operating Margin 7.5% -0.6%
EPS -4.35 -1.39
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.